📊 AI Stock Rating — Summary

Amdocs Limited reported revenue of $1.15 billion and a net income of $97.1 million for the quarter ending September 2025, resulting in an EPS of $0.88. The net profit margin stands at approximately 8.4%. The company generated a solid free cash flow (FCF) of $198.6 million, demonstrating a strong ability to turn operating cash flows into cash available for investors after capital expenditures. However, the absence of FCF data in the provided metrics should be noted for a precise comparison. Amdocs has a robust capital structure with $3.47 billion in total equity against $501.4 million in net debt, indicating a cautious approach to leverage. In terms of shareholder returns, the company returned capital through $136.4 million in stock repurchases and $57.9 million in dividends. The stock is supported by a consensus price target of $97.8, hinting at potential upside. Revenue growth appears steady while profitability metrics suggest operational efficiency. Combined, these data points create a coherent picture of a stable enterprise poised for continued strength.

AI Score Breakdown

Revenue Growth — Score: 6/10

Amdocs' quarterly revenue of $1.15 billion shows stable growth, supported by consistent year-over-year increments. Key drivers stem from existing client verticals and new project acquisitions.

Profitability — Score: 7/10

With an EPS of $0.88 and a net margin of 8.4%, Amdocs exhibits solid profitability. The operational efficiencies are highlighted by steady operating cash flows.

Cash Flow Quality — Score: 8/10

Free cash flow of $198.6 million underscores strong liquidity and operational cash generation. Share repurchases and dividends further reinforce positive cash flow management.

Leverage & Balance Sheet — Score: 8/10

The balance sheet reflects financial resilience with $3.47 billion in equity against $501.4 million in net debt, illustrating conservative financial management and a comfortably leveraged profile.

Shareholder Returns — Score: 7/10

Through $136.4 million in buybacks and $57.9 million in dividends, Amdocs maintains shareholder-friendly practices. Price targets up to $105 suggest further potential upside.

Analyst Sentiment & Valuation — Score: 6/10

With a consensus price target of $97.8, Amdocs appears fairly valued. The absence of detailed valuation metrics limits deeper assessment, yet analyst forecasts remain positive.

⚠ AI-generated — informational only, not financial advice.